B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, a clone's intrinsic potential for in vitro growth correlated directly with doubling time in blood, in the case of B-CLL with Ig H chain V region-unmutated BCR and <30% CD38(+) cells in blood.
|
26136429 |
2015 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present results further confirm that IGH@ rearrangement is not a rare genomic abnormality in B-CLL, and also show both that t(14;19)(q32;q13.2) is the most common cytogenetic change involving IGH@ rearrangement detected by FISH in B-CLL and that IGH@ rearrangement is correlated with CD38 expression.
|
19963136 |
2010 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
For this report we studied HLA-G in parallel with CD38 and ZAP-70 in B-cell chronic lymphocytic leukemia (B-CLL) patients.
|
19298722 |
2009 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our data show that CD38 SNPs may affect CD38 expression and contribute to the increased risk of B-CLL carcinogenesis.
|
19240243 |
2009 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Multivariate analysis revealed that CD38 expression level on T cells is an independent prognostic factor in B-CLL male patients.
|
19247976 |
2009 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether these results suggest that: i) CD38-expressing cells present not only an activation status, but also a different stage differentiation with a more repeated turnover; ii) CD38 contributes to controlling a signaling pathway that confers to B-CLL cells an increased proliferative potential, enhancing aggressiveness of this variant; iii) different CD38 cut off values should be considered for peripheral blood and bone marrow; iv) CD38 seems to independently contribute to prognostic stratification of B-CLL.
|
17380202 |
2007 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Flow cytometry performed on 5 cases showed the typical B-CLL immunophenotype; all were CD38-, but 3 expressed ZAP-70.
|
17145621 |
2007 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia.
|
17875758 |
2007 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We investigated hTERT gene expression in 134 B-cell chronic lymphocytic leukemia (B-CLL) cases and evaluated its prognostic value with other prognostic markers (IgVH mutation status, CD38 and ZAP-70 expression).
|
17344921 |
2007 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of three approaches to analyze its expression.
|
16568475 |
2006 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated the 70-kDa zeta-associated protein (ZAP-70), CD38, soluble CD23 (sCD23), and cytogenetics in 289 patients with B-CLL.
|
16601244 |
2006 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further studies are needed to elucidate the underlying mechanisms of the sex-specific role of CD38+ T cells in B-CLL.
|
16825496 |
2006 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Molecular markers like IgV(H) mutational status, chromosomal abnormalities, and CD38 and ZAP-70 expression have prognostic value in B-cell chronic lymphocytic leukemia (B-CLL).
|
16332969 |
2006 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DNA microarray technology was employed to compare eight ZAP-70+CD38+ with eight ZAP-70-CD38- B-CLL cases.
|
16932341 |
2006 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
With the addition of rituximab to fludarabine, improved clinical outcomes were obtained, and the stratification of patients by using ZAP-70 and CD38 may help clinicians offer more aggressive and/or experimental approaches to the treatment of patients with high-risk B-CLL subtypes.
|
16284990 |
2005 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Chromosomal aberrations and CD38 expression in two siblings with B-cell chronic lymphocytic leukemia: a report of two siblings.
|
15621833 |
2005 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
This in turn may explain the biological and clinical differences between CD38-positive type B-CLL and CD38-negative type B-CLL.
|
16208411 |
2005 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A hierarchical clustering focused on B-CLLs alone, combining reactivity values for B-mAbs with the expression of CD62L and CD38, these latter antigens identified as leader markers of B-CLL subsets with different prognosis, demonstrated a correlation between CD62L expression and the reactivity of B007, B003, B011 and B005 mAbs.
|
16198366 |
2005 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
Over-representation of high-risk genomic aberrations such as 17p deletion or 11q deletion and distribution of the IgV(H) mutation status in B-CLL discordant for ZAP-70/CD38 pointed toward a distinct biologic background of the observed disease subgroups.
|
15759031 |
2005 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL).
|
15160906 |
2004 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study tests the hypothesis that soluble p53 alone and in association with CD38 can enucleate B-CLL subsets at worse prognosis.
|
15590397 |
2004 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results showed that B-CLLs display a common gene expression profile that is largely independent of CD38 expression.
|
12456497 |
2003 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, the relationship between CD38 expression and Ig VH mutation status in B-CLL is not straightforward.
|
11843819 |
2001 |
B-CELL MALIGNANCY, LOW-GRADE
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One patient with morphologically atypical B-CLL had t(1;11)(p36;q13) together with der(X)t(X;?)(q26;?), der(3)t(3;?)(q29;?), der(8)t(4;8)(q12;q24.1) and additional variable changes.
|
1913607 |
1991 |